Pharmadrug Inc. Stock

Equities

PHRX

CA71716W2040

Pharmaceuticals

Market Closed - Canadian Securities Exchange 03:55:08 2024-04-19 pm EDT 5-day change 1st Jan Change
0.035 CAD 0.00% Intraday chart for Pharmadrug Inc. 0.00% -36.36%
Sales 2021 0.49 0.68 Sales 2022 - Capitalization 5.33M 7.33M
Net income 2021 -5M -6.87M Net income 2022 -8M -11M EV / Sales 2021 23,231,869 x
Net cash position 2021 429K 590K Net Debt 2022 1.09M 1.5M EV / Sales 2022 -
P/E ratio 2021
-2.06 x
P/E ratio 2022
-0.59 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 99.12%
More Fundamentals * Assessed data
Dynamic Chart
1 month-12.50%
3 months-22.22%
Current year-36.36%
More quotes
1 week
0.03
Extreme 0.03
0.04
1 month
0.03
Extreme 0.03
0.04
Current year
0.03
Extreme 0.03
0.08
1 year
0.03
Extreme 0.025
0.08
3 years
0.03
Extreme 0.025
0.84
5 years
0.03
Extreme 0.025
1.82
10 years
0.03
Extreme 0.025
4.55
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-05
Chief Tech/Sci/R&D Officer - 21-05-12
Members of the board TitleAgeSince
Director/Board Member 80 16-12-19
Director/Board Member 58 19-05-30
Chairman - 21-08-29
More insiders
Date Price Change Volume
24-04-19 0.035 0.00% 39,070
24-04-18 0.035 0.00% 47,725
24-04-17 0.035 0.00% 23,285
24-04-15 0.035 0.00% 187,399
24-04-12 0.035 0.00% 12,854

Delayed Quote Canadian Securities Exchange, April 19, 2024 at 03:55 pm EDT

More quotes
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.
More about the company